ATE262329T1 - Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln - Google Patents

Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln

Info

Publication number
ATE262329T1
ATE262329T1 AT98953570T AT98953570T ATE262329T1 AT E262329 T1 ATE262329 T1 AT E262329T1 AT 98953570 T AT98953570 T AT 98953570T AT 98953570 T AT98953570 T AT 98953570T AT E262329 T1 ATE262329 T1 AT E262329T1
Authority
AT
Austria
Prior art keywords
toxicity
reducing
agents
formulations
methods
Prior art date
Application number
AT98953570T
Other languages
English (en)
Inventor
Frederick H Hausheer
Thomas J Dodd
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE262329T1 publication Critical patent/ATE262329T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT98953570T 1997-10-17 1998-10-16 Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln ATE262329T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,678 US5919816A (en) 1994-11-14 1997-10-17 Formulations and methods of reducing toxicity of antineoplastic agents
PCT/US1998/021814 WO1999020264A1 (en) 1997-10-17 1998-10-16 Formulations and methods for reducing toxicity of antineoplastic agents

Publications (1)

Publication Number Publication Date
ATE262329T1 true ATE262329T1 (de) 2004-04-15

Family

ID=25495777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98953570T ATE262329T1 (de) 1997-10-17 1998-10-16 Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln

Country Status (12)

Country Link
US (11) US5919816A (de)
EP (1) EP1033981B1 (de)
JP (3) JP2001520189A (de)
CN (1) CN1276720A (de)
AT (1) ATE262329T1 (de)
AU (1) AU750521B2 (de)
CA (1) CA2304704C (de)
DE (1) DE69822659T2 (de)
DK (1) DK1033981T3 (de)
ES (1) ES2213922T3 (de)
PT (1) PT1033981E (de)
WO (1) WO1999020264A1 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6197831B1 (en) * 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6075053A (en) * 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6395481B1 (en) 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US20030036513A1 (en) * 1999-02-16 2003-02-20 Yurkow Edward J. Method for treating cancer
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
CA2369303A1 (en) * 1999-04-14 2000-10-19 Arthur B. Pardee Method and composition for the treatment of cancer
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
EP1171117A4 (de) * 1999-04-22 2002-08-07 American Bioscience Inc Langzeitverabreichung von pharmakologisch aktiven mitteln
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6034126A (en) * 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP2266607A3 (de) 1999-10-01 2011-04-20 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
CA2391382A1 (en) * 1999-11-15 2001-05-25 Parker Hughes Institute Phorboxazole derivatives for treating cancer
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
AU2000239101A1 (en) * 2000-03-22 2001-10-03 Neopharm, Inc. A method of administering liposomal encapsulated taxane
GB0011927D0 (en) * 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
SK7092003A3 (en) 2000-11-09 2004-06-08 Neopharm Inc SN-38 lipid complexes and methods of use
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
MXPA03006359A (es) * 2001-01-19 2004-04-20 Bionumerik Pharmaceuticals Inc Metodo para tratamiento del cancer.
US20030149096A1 (en) * 2001-02-05 2003-08-07 Pezzuto John M. Cancer chemopreventative compounds and compositions and methods of treating cancers
CZ20032266A3 (cs) * 2001-03-06 2004-02-18 Bristol-Myers Squibb Company Dávkovací formy pro ošetřování nádorů
DK1372650T3 (da) * 2001-03-19 2009-03-16 Novartis Ag Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
DK1482973T3 (da) 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
JP2005531560A (ja) * 2002-05-17 2005-10-20 レオ・ファーマ・アクティーゼルスカブ シアノグアニジンプロドラッグ
BR0309996A (pt) * 2002-05-17 2005-02-22 Leo Pharma As Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
EP1511478A4 (de) 2002-05-31 2009-12-02 Pharmagenesis Inc Triptolid-derivate zur modulierung der apoptose und immunosuppression
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
WO2004022699A2 (en) * 2002-09-05 2004-03-18 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2004054569A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
JP4711947B2 (ja) * 2003-02-03 2011-06-29 ネオファーム、インコーポレイティッド 安定な濾過滅菌性リポソームに被包化されたタキサン及び他の抗腫瘍剤
CA2527320A1 (en) * 2003-05-30 2004-12-16 University Of Chicago Methods and compositions for predicting irinotecan toxicity
US20040266808A1 (en) * 2003-06-27 2004-12-30 Kamen Barton A. Treatment of antifolate neurotoxicity
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
WO2005077008A2 (en) * 2004-02-09 2005-08-25 Pharmagenesis, Inc. Methods for isolation of triptolide compounds from tripterygium wilfordii
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
ATE554758T1 (de) * 2004-03-02 2012-05-15 Pharmagenesis Inc Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
US7200207B2 (en) * 2004-03-13 2007-04-03 Intrado Inc. Communication network for providing emergency services
US7605137B2 (en) * 2004-03-26 2009-10-20 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
WO2006023883A2 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel inhibitors
US20060063742A1 (en) * 2004-09-21 2006-03-23 Hausheer Frederick H Method of treatment for or protection against lymphedema
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US8617906B2 (en) * 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
WO2006066584A1 (en) * 2004-12-22 2006-06-29 Leo Pharma A/S Novel cyanoguanidine compounds
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
US8026227B2 (en) * 2005-12-13 2011-09-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
CN101663040A (zh) * 2007-02-09 2010-03-03 帕纳德制药公司 包封的吡铂
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008106721A1 (en) * 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
CA2701071C (en) * 2007-09-26 2018-03-27 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
AU2008326461B2 (en) * 2007-11-20 2014-11-13 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
US20110053879A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
JP5504179B2 (ja) 2008-03-03 2014-05-28 トスク インコーポレーティッド 毒性を低減するためのメトトレキセートアジュバントおよびその使用法
EP3028743A3 (de) * 2008-03-05 2017-01-25 Vicus Therapeutics, LLC Zusammensetzungen für mukositis- und onkologietherapien
EP2252246B1 (de) * 2008-03-14 2014-06-18 Bionumerik Pharmaceuticals, Inc. Chemoprotektive verfahren und zusammensetzungen
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
AU2008352603B2 (en) * 2008-03-14 2012-05-31 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
EP2249825B1 (de) * 2008-03-14 2015-10-07 Bionumerik Pharmaceuticals, Inc. Behandlungsverfahren und zusammensetzungen gegen lungenkrebs, adenokarzinom und andere medizinische krankheitszustände
US8697391B2 (en) 2009-05-15 2014-04-15 Lankenau Institute For Medical Research Method of determining cell number or viability using hydroxyethyldisulfide
SG183114A1 (en) 2010-03-01 2012-09-27 Tau Therapeutics Llc Cancer diagnosis and imaging
CN103221388B (zh) * 2010-07-09 2016-09-28 维理生物技术公司 用于抑制转移性肿瘤生长的新型磺酰胺化合物
US9271952B2 (en) * 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
CN102871991B (zh) * 2012-10-24 2014-06-18 中国医学科学院放射医学研究所 二甲双胍在对放化疗损伤起保护作用的药物中的应用
WO2015017803A1 (en) * 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
US9470029B2 (en) 2014-05-30 2016-10-18 Pella Corporation Casement pivot arm roller hinge
HUE053968T2 (hu) 2015-07-07 2021-08-30 H Lundbeck As Triazinon vázzal és imidazo-pirazinon vázzal rendelkezõ PDE9 inhibitorok perifériás betegségek kezelésére
EP3355879A4 (de) 2015-10-02 2019-05-22 Complexa, Inc. Vorbeugung, behandlung und umkehr von erkrankungen mit therapeutisch wirksamen mengen von aktivierten fettsäuren
DK3801526T3 (da) 2018-05-25 2024-03-25 Cardurion Pharmaceuticals Inc Monohydrate og krystallinske former af 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imidazo[1,5-a]pyrazin-8-on
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2806866C3 (de) * 1978-02-17 1981-02-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

Also Published As

Publication number Publication date
JP2001520189A (ja) 2001-10-30
JP2006070041A (ja) 2006-03-16
CA2304704C (en) 2009-01-13
JP2010043117A (ja) 2010-02-25
US6040312A (en) 2000-03-21
EP1033981B1 (de) 2004-03-24
EP1033981A1 (de) 2000-09-13
DE69822659T2 (de) 2004-08-12
PT1033981E (pt) 2004-08-31
US6057361A (en) 2000-05-02
AU1090899A (en) 1999-05-10
WO1999020264A1 (en) 1999-04-29
US6046159A (en) 2000-04-04
US6040294A (en) 2000-03-21
US5919816A (en) 1999-07-06
US6066668A (en) 2000-05-23
ES2213922T3 (es) 2004-09-01
CN1276720A (zh) 2000-12-13
CA2304704A1 (en) 1999-04-29
US6040304A (en) 2000-03-21
US6043249A (en) 2000-03-28
EP1033981A4 (de) 2001-10-04
AU750521B2 (en) 2002-07-18
US6048849A (en) 2000-04-11
US6046234A (en) 2000-04-04
DK1033981T3 (da) 2004-07-12
DE69822659D1 (de) 2004-04-29
US6066645A (en) 2000-05-23

Similar Documents

Publication Publication Date Title
ATE262329T1 (de) Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
DE69525291D1 (de) Bisphosphonat und anti-Resorption Agentien, enthaltende Zusammensetzungen zur Hemmung der Knochenschwund
DK0975595T3 (da) Kokainanaloger
EP0722324A4 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
EP0693924A4 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
TR199902253T2 (xx) �n g�z odac���nda farmas�tik maddelerin kontroll� sal�n�m�.
EP1478406A4 (de) Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
PT1146861E (pt) Formulacoes de particulas de hidrogel
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
ATE102604T1 (de) Diarylverbindungen als antiatherosklerotische mittel.
DE69322251D1 (de) Medizinische zusammensetzung
BR9711986A (pt) Compostos farmac-uticos
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR200103144T2 (tr) Yeni bileşikler
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1033981

Country of ref document: EP